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Comparison of Ertapenem and Ceftriaxone Therapy for Acute 
Pyelonephritis and Other Complicated Urinary Tract Infections in 
Korean Adults: A Randomized, Double-Blind, Multicenter Trial
The efficacy and safety of ertapenem, 1 g once daily, were compared with that of 
ceftriaxone, 2 g once daily, for the treatment of adults with acute pyelonephritis (APN) 
and complicated urinary tract infections (cUTIs) in a prospective, multicenter, double-
blinded, randomized study. After ≥ 3 days of parenteral study therapy, patients could be 
switched to an oral agent. Of 271 patients who were initially stratified by APN (n = 210) or 
other cUTIs (n = 61), 66 (48.9%) in the ertapenem group and 71 (52.2%) in the ceftriaxone 
group were microbiologically evaluable. The mean duration of parenteral and total therapy, 
respectively, was 5.6 and 13.8 days for ertapenem and 5.8 and 13.8 days for ceftriaxone. 
The most common pathogen was Escherichia coli. At the primary efficacy endpoint 
5-9 days after treatment, 58 (87.9%) patients in the ertapenem group and 63 (88.7%) in 
the ceftriaxone had a favorable microbiological response. When compared by stratum and 
severity, the outcomes in the two groups were equivalent. The frequency and severity of 
drug-related adverse events were generally similar in both treatment groups. The results 
indicate that ertapenem is highly effective and safe for the treatment of APN and cUTIs.
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INTRODUCTION
Urinary tract infections (UTIs) are considered the most common 
bacterial infections with an estimated annual global incidence 
of at least 250 million cases and are costly to both patients and 
healthcare funding systems (1, 2). Most UTIs are uncomplicated 
cystitis caused by Escherichia coli in otherwise healthy young 
women, which are easily managed with short-term oral antibi-
otic therapy. In contrast, acute pyelonephritis (APN) occurring 
in this same population requires often hospitalization and pro-
longed therapy. According to the recent report on APN in the 
Republic of Korea (ROK) (3), average annual incidence rate was 
35.7 per 10,000 population, and approximately one of every sev-
en patients was hospitalized. Treatment of complicated UTIs 
(cUTIs), including APN requires 10-14 days with an antibiotic 
agent active against various gram-negative bacilli (4-8). For these Park DW, et al.  •  Comparing Ertapenem and Ceftriaxone for Complicated Urinary Tract Infections 
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infections, a sequential approach with initial parenteral therapy 
and subsequent adequate oral agent with a more prolonged 
course could be considered an option as a standard therapy (9). 
However, clinical trials for UTIs have been relatively limited. 
Given the importance of these infections, further studies are 
needed to develop how they should be managed. Furthermore, 
increasing resistance among E. coli requires continuing reassess-
ment of empirical therapy or more alternative first-line agents 
(10, 11).
  Ertapenem, a long-acting parenteral group 1 carbapenem, has 
excellent in vitro activity against many gram-positive and gram-
negative aerobic and anaerobic pathogens, except for Pseudo-
monas aeruginosa, Acinetobacter species, methicillin-resistant 
staphylococci and enterococci (12). Based on several random-
ized clinical trials performed in other countries, ertapenem ad-
ministered at 1 g once-a-day is safe and effective in the treat-
ment of complicated intra-abdominal infections, acute pelvic 
infections, community-acquired pneumonia, skin and soft-tis-
sue infections, and cUTIs (13-16). However, the safety and effi-
cacy of ertapenem in randomized clinical trials has not been 
evaluated in the Korean population.
  The objectives of this study were to compare the efficacy, tol-
erability, and safety of ertapenem, 1 g once a day, with that of 
ceftriaxone, 2 g once a day, followed by an optional oral thera-
py, for the treatment of APN or other cUTIs in a Korean adult 
population. 
MATERIALS AND METHODS
Study design and antimicrobial therapy
The double-blinded, prospective, randomized study was con-
ducted in 9 university hospitals in the ROK from April 2008 to 
February 2009. The study design was based on the previous clin-
ical trial for the treatment of complicated urinary tract infections 
(17). Eligible patients were stratified according to the diagnosis 
of APN (with or without an abnormality of the urinary tract) or 
other cUTIs. Patients were sequentially randomized to one of 
two treatment regimens in a 1:1 ratio using a stratified random-
ization schedule by the pharmacist. 
  Ertapenem (1 g once daily) or ceftriaxone (2 g once daily) was 
given by the intravenous (i.v.) route over 30 min. Patients received 
at least 3 doses of i.v. therapy before being switched to oral ther-
apy. Oral agent was usually ciprofloxacin (500 mg bid). However, 
cefixime (200 mg bid) were permitted if the patient could not 
tolerate ciprofloxacin or if the causal pathogen was resistant to 
ciprofloxacin. The decision to switch from i.v. therapy to oral 
therapy was made by the investigator, if the patient was afebrile 
for at least 24 hr; nausea and vomiting were resolved; signs, symp-
toms and leukocytosis had improved; and urine culture was ob-
tained. The suggested total duration of parenteral drug alone or 
parenteral plus an oral antibiotics was 7-14 days. The dosages 
selected for the comparator and oral agents were the usual rec-
ommended doses for the cUTIs in Korea.
Patients
Korean patients aged  ≥ 18 yr with cUTI or APN who required 
parenteral antibiotic therapy were eligible for the study. The cri-
teria for APN included fever, flank pain or costovertebral angle 
tenderness, pyuria (≥ 10 white blood cell per high power field), 
and followed by positive urine culture (≥ 10
5 colony forming 
unit [CFU] of uropathogen/mL) (18). Criteria for other cUTI in 
males were signs or symptoms of UTI, pyuria, and positive urine 
culture; female patients were additionally required to have either 
an indwelling catheter, current bladder catheterization, instru-
mentation of the urinary tract, or functional or anatomic abnor-
mality of the urinary tract (18). 
  The exclusion criteria included pregnancy or lactation in 
women, history of serious allergy or intolerance to either study 
drug, a baseline pathogen resistant to either study drug, treat-
ment for  > 24 hr of effective antimicrobial agents within 72 hr 
prior to enrolment, complete obstruction of the urinary tract, 
perinephric or intrarenal abscess, prostatitis, any rapidly pro-
gressive or terminal diseases, renal transplantation, requirement 
for peritoneal dialysis or hemodialysis, creatinine clearance of 
≤ 30 mL/min, and absolute neutrophil count  < 1,000/μL. 
Clinical assessments
Clinical assessments, including detailed description and evalu-
ation of the infectious process, was performed at admission, at 
the discontinuation of i.v. therapy (DCIV), and at the early fol-
low-up visit (EFU, 5-9 days post-therapy). Clinical responses at 
the EFU visit were assessed as cure, failure, or indeterminate. 
Cure was defined as resolution of all or most pre-therapy signs 
and symptoms and no additional antibiotics required. Failure 
was defined as persistence or progression of most/all pre-ther-
apy signs and symptoms. Indeterminate was applicable when 
study data were not available for evaluation of efficacy. 
Microbiological assessments
Blood culture and quantitative urine culture were performed at 
baseline. All isolates were identified at each site laboratory, and 
pathogens were tested for in vitro susceptibility to ertapenem, 
ceftriaxone, and ciprofloxacin according to the guidelines of the 
Clinical Laboratory Standard Institute (19). 
  Microbiological response for each pathogen present in the 
admission urine culture was assessed separately at DCIV and 
EFU visit. Microbiological responses at DCIV and EFU visit were 
defined as eradication (uropathogen  ≥ 10
5 CFU/mL at entry 
reduced to  < 10
4 CFU/mL), persistence (urine culture grew 
≥ 10
4 CFU/mL of an original uropathogen), persistence with 
acquisition of resistance, superinfection (urine culture during 
therapy grew  ≥ 10
5 CFU/mL of a pathogen other than baseline Park DW, et al.  •  Comparing Ertapenem and Ceftriaxone for Complicated Urinary Tract Infections 
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pathogen), or new infection (urine culture after completion of 
therapy grew  ≥ 10
5 CFU/mL of a pathogen other than baseline 
pathogen). Overall microbiological response was determined 
as “favorable” (eradication) or “unfavorable” (persistence, per-
sistence with acquisition of resistance, superinfection or new 
infection). 
Populations for analysis
The treated population included all randomized patients who 
received one or more doses of study therapy. The microbiologi-
cal modified intention-to-treat (MITT) population included 
treated patients who met the minimal definition of APN or other 
cUTI, and who had a baseline pathogen isolated in any quanti-
ty, and had a follow-up urine culture at or after DCIV. The clini-
cally evaluable population met the following criteria: patients 
who had clinical evidence of APN or cUTI, had baseline uro-
pathogen present at  ≥ 10
5 CFU/mL, at least one baseline patho-
gen susceptible to both parenteral study drugs. Microbiologi-
cally evaluable patients were those clinically evaluable patients 
who had a follow-up urine culture at the EFU visit.
Efficacy variables
The primary efficacy endpoint was based on the proportion of 
patients who had a favorable microbiological response in the 
microbiologically evaluable patients at the EFU visit. Additional 
efficacy assessments were the microbiological response rates in 
the microbiological MITT population and combined microbio-
logical and clinical response rates in evaluable patients at the 
DCIV and EFU visit. 
Safety and tolerability assessment
All patients who received at least one dose of study therapy were 
evaluated for safety. Patients were monitored for adverse events 
(AEs) on a daily basis during parenteral therapy and for 14 days 
after the discontinuation of study antibiotic therapy. The tolera-
bility of each parenteral study drug at the local infusion site was 
evaluated daily. The primary safety endpoints were the propor-
tion of patients within each treatment group who experience 
any drug-related AEs leading to discontinuation of parenteral 
study drug. 
Statistical analyses
The study was designed to show non-inferiority in efficacy of the 
ertapenem compared to ceftriaxone in microbiologically evalu-
able treatment groups at EFU visit. The definition of non-inferi-
ority is the lower limit of the 95% (two-sided) confidence interval 
(CI) for the difference in response rates between the two groups 
does not exceed -20 percentage points and the CI contains zero. 
The sample size was calculated with the following values: alpha, 
0.05; beta, 0.10; the expected response rate for each of the treat-
ment groups, 85%, and the delta was set at -0.20. Assuming 85% 
response rates for both groups and a significance level of 0.05, a 
total of 134 evaluable patients (67 patients per group) are need-
ed in order to have 90% probability that the lower limit of 95% 
(two-sided) CI for the difference in the response rates between 
the two groups is not less than -20 percentage points. 
  The strata were accounted for in testing the hypotheses for 
efficacy. For each endpoint at relevant time points, the differ-
ence in response proportion between two groups was displayed 
with its 95% (two-sided) CI. All CIs were calculated using the 
normal approximation to the binomial distribution. The CI for 
the difference between treatment groups was calculated using 
an adjustment for stratification. The Mantel-Haenszel method 
was used to calculate the stratified CI. Kaplan-Meier estimate 
was performed to explore time to discontinuation of parenteral 
therapy. The SAS software (version 9.1; SAS Institute, Cary, NC, 
USA) was used for analysis.
Ethics statements
The institutional review board of Korea University Anam Hos-
pital and each study site reviewed and approved the study pro-
tocol (approved number of Korea University Anam Hospital: 
ED07154). Written informed consent was obtained from all par-
ticipating patients.  
RESULTS
Patients and therapy
A total of 271 patients were randomized, 135 to the ertapenem 
group and 136 to the ceftriaxone group, of which 66 (48.9%) and 
71 (52.2%) were microbiologically evaluable, respectively (Fig. 1). 
The most common reason for the microbiologically not evalu-
able populations was failure to isolate an uropathogen or  ≥ 10
5 
CFU/mL at baseline: 38 (28.1%) in the ertapenem group and 43 
(31.6%) in the ceftriaxone group. 
  Baseline demographics, clinical characteristics and treatment 
duration in the randomized and microbiologically evaluable 
populations were similar across the treatment groups (Table 1). 
Hypertension and diabetes mellitus were the most frequent co-
morbid diseases in the randomized population: respectively,  
48 patients (35.6%) and 39 (28.9%) in the ertapenem group; 54 
(39.7%) and 31 (22.8%) in the ceftriaxone group. In the random-
ized patients, 10 (7.4%) patients in the ertapenem group and 
seven (5.1%) in the ceftriaxone group had indwelling catheters 
or stents: in the microbiologically evaluable population, seven 
(10.6%) patients in the ertapenem group and one (1.4%) patients 
in the ceftriaxone group, respectively.
  The mean duration of parenteral and total study drug thera-
py, respectively, in the microbiologically evaluable patients was 
5.6 days and 13.8 days for those treated with ertapenem, and 5.8 
days and 13.8 days for those treated with ceftriaxone. Almost all 
patients in each treatment group were switched to oral therapy: Park DW, et al.  •  Comparing Ertapenem and Ceftriaxone for Complicated Urinary Tract Infections 
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51 (77.3%) and 14 (19.7%) in the ertapenem group and 62 (87.3%) 
and eight (11.3%) in the ceftriaxone group were switched to cip-
rofloxacin and cefixime, respectively. 
Baseline microbiology 
Of the 217 isolates from all randomized patients, E. coli was the 
most common pathogen (n = 185, 85.3%), followed by Klebsiella 
pneumoniae (n = 10, 4.6%) (Table 2). Among the E. coli isolates 
tested, nonsusceptibility rates to ertapenem and ceftriaxone 
were 0.6% (1/158) and 6.2% (11/177), respectively. Extended-
spectrum β-lactamase (ESBL) producing E. coli isolates account-
ed for 4.3% (7/94) in the ertapenem group and 4.5% (4/88) in the 
ceftriaxone group. The susceptible rate to ciprofloxacin among 
the E. coli isolates were 77.7% (143/184): 69.9% (65/93) in ertap-
enem group and 85.7% (78/91) in ceftriaxone group. In the micro-
biologically evaluable population, distribution of the pathogens 
and their susceptibility profiles were comparable in the two treat-
ment groups. 
  Forty five patients who received ertapenem and 46 treated 
with ceftriaxone were bacteremic at baseline. E. coli was the  
271 Randomized to study groups
135 Randomized to ertapenem group
132 Included in clinical MITT population
136 Randomized to ceftriaxone group
135 Included in clinical MITT population
70 Included clinically evaluable  
population
76 Included clinically evaluable  
population
66 Included microbiologically evaluable  
population
71 Included microbiologically evaluable  
population
102 Included in 
microbiological MITT 
population
100 Included in 
microbiological MITT 
population
Fig. 1. Profile of patient enrollment.
Table 1. Baseline and clinical characteristics and duration of study therapy in randomized and microbiologically evaluable patients by treatment group
Characteristics
Randomized Microbiologically evaluable
Ertapenem (n = 135) Ceftriaxone (n = 136) Ertapenem (n = 66) Ceftriaxone (n = 71)
Gender
   Male
   Female
 
     16 (11.9%)
   119 (88.1%)
 
   10 (7.4%)
126 (92.6)
 
  7 (10.6)
59 (89.4)
 
3 (4.2)
68 (95.8)
Age (yr)
   18-64
   > 65
   Mean ± SD
   Median (range)
 
  80 (59.3)
  55 (40.7)
  55.4 ± 19.5
    57 (19-85)
 
  87 (63.9)
  49 (36.1)
  56.5 ± 17.6
 59.5 (18-88)
 
34 (51.5)
32 (48.5)
  58.4 ± 20.1
62.5 (19-85)
 
48 (67.6)
23 (32.4)
  57.0 ± 17.2
  60 (19-88)
Duration of symptoms (days)*
   Mean ± SD
   Median (range)
 
  4.1 ± 4.6
    3 (1-45)
 
  4.7 ± 6.4
    3 (1-60)
 
  4.5 ± 5.8
   3 (1-45)
 
  4.5 ± 4.5
  3 (1-30)
Stratum
   APN
   Other cUTI
 
103 (76.3)
  32 (23.7)
 
107 (78.7)
  29 (21.3)
 
51 (77.3)
15 (22.7)
 
57 (80.3)
14 (19.7)
Days on therapy (mean ± SD)
†
   Intravenous
   Oral
   Total
 
  4.8 ± 2.0
  5.4 ± 4.1
10.1 ± 5.2
 
  4.8 ± 2.1
  5.1 ± 4.1
10.0 ± 5.1
 
  5.6 ± 1.6
  8.2 ± 1.7
13.8 ± 0.9
 
  5.8 ± 1.9
  8.0 ± 2.0
13.8 ± 1.2
*The duration of symptoms prior to study entry; 
†In randomized patients: for ertapenem, n = 132; for ceftriaxone, n = 135. SD, standard deviation; APN, acute pyelonephritis; 
cUTI, complicated urinary tract infection.Park DW, et al.  •  Comparing Ertapenem and Ceftriaxone for Complicated Urinary Tract Infections 
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etiologic agent in 83 (91.2%) of these patients. Of those tested, 
25.6% (10/39) and 10% (4/40) were resistant to ciprofloxacin in 
each group. ESBL-producers were 7.5% (3/40) in each group. 
Efficacy
Microbiological response rates by stratum and time of assess-
ment are shown in Table 3. At the primary efficacy endpoint, 
87.9% patients in the ertapenem group and 88.7% in the ceftri-
axone group had a favorable microbiological response assess-
ment. The difference in the microbiological response rates, ad-
justing for strata, was -0.8% (95% CI, -11.7 to 10.2), indicating 
equivalence between the two treatments. Microbiological re-
Table 2. Antibiotic susceptibility of baseline pathogen isolated from all randomized patients
Pathogens
Isolates from ertapenem group Isolates from ceftriaxone group
N
Ertapenem Ceftriaxone Ciprofloxacin
N
Ertapenem Ceftriaxone Ciprofloxacin
n
Suscep- 
tible
n
Suscep- 
tible
n
Suscep- 
tible
n
Suscep- 
tible
n
Suscep- 
tible
n
Suscep- 
tible
Gram-negative bacilli 107 104
Escherichia coli   94 79 79 (100) 88 83 (94.3) 93 65 (69.9)   91 79 78 (98.7) 89 83 (93.3) 91 78 (85.7)
Klebsiella pneumoniae     5   4   4 (100)   5  5 (100)   5  5 (100)     5   5  5 (100)   5  5 (100) 5  5 (100)
Citrobacter koseri     1   1   1 (100)   1  1 (100)   1  1 (100)
Citrobacter freundii     2   2   2 (100)   2   1 (50.0)   2  2 (100)
Enterobacter cloacae     5   3  3 (100)   5   4 (80.0)   5  5 (100)
Serratia macrcescens     2   2   2 (100)   2   1 (50.0)   2   1 (50.0)     1   1  1 (100)   1  1 (100)   1  1 (100)
Proteus mirabilis     1   1   1 (100)   1  1 (100)   1  1 (100)     1   1  1 (100)   1 0   1 0
Morganella morganii     1   1   1 (100)   1  1 (100)   1  1 (100)
Pseudomonas aeruginosa     1   1 0   1 0   1 0     1   0 0   1 0   1  1 (100)
Gram-positive cocci     5     1
Staphylococcus aureus     2   2    1 (50.0)   2   1 (50.0)   2 0 
Streptococcus spp.     3   3   3 (100)   3  3 (100)   3   2 (66.7)     1   1  1 (100)   1  1 (100)   1  1 (100)
N, number of isolates; n, number of isolates tested.
Table 3. Favorable microbiologic response assessments in microbiologically evaluable patients with APN or other cUTI, by stratum and time of assessment
Patients
Ertapenem (n = 66) Ceftriaxone (n = 71)
     Observed  
     differences (A-B)% No. favorable/ 
No. assessed
% Response (95% CI)
No. favorable/ 
No. assessed
% Response (95% CI)
DCIV
   Acute pyelonephritis
   Other complicated UTI
   Overall
 
51/51
14/15
65/66
 
   100 (99.0-100.0)
  93.3 (77.4-100.0)
  98.5 (94.8-100.0)
   
53/57
13/14
66/71
 
  93.0 (85.5-100.0)
  92.9 (75.8-100.0)
93.0 (86.3-99.6)
 
7.0
0.5
5.6 
EFU
   Acute pyelonephritis
   Other complicated UTI
   Overall
 
45/51
13/15
58/66
 
88.2 (78.4-98.1)
  86.7 (66.1-100.0)
87.9 (79.3-96.5)
   
51/57
12/14
63/71
 
89.5 (80.6-98.3)
  85.7 (63.8-100.0)
88.7 (80.7-96.8)
 
-1.2
1.0
-0.8
APN, acute pyelonephritis; cUTI, complicated urinary tract infection; N, number of evaluable patients in each treatment group; CI, confidence interval; DCIV, discontinuation of 
intravenous (i.v.) therapy includes patients who completed a regimen of i.v. therapy only and patients who discontinued i.v. and then switched to oral therapy; EFU, early follow-
up visit, 5-9 days post-therapy.
Table 4. Eradication rates at early follow up in microbiologically evaluable patients* with acute pyelonephritis or other complicated UTI by baseline pathogen
Pathogens
Ertapenem (n = 66) Ceftriaxone (n = 71)      Observed  
     differences (A-B)% n/m % Response (95% CI) n/m % Response (95% CI)
Gram-negative bacilli
   Citrobacter spp.
   E. cloacae
   E. coli
   K. pneumoniae
   P. mirabilis
   S. marcescens
58/66
2/2
 
53/60
1/3
1/1
1/1
      87.9 (79.2-96.5)
100
 
      88.3 (79.4-97.3)
33.3 (0-100)
100
100
62/70
 
3/4
56/62
2/4
 
1/1
      88.6 (80.4-96.7)
 
     75.0 (20.1-100)
      90.3 (82.2-98.5)
50.0 (0-100)
 
100
-0.7
 
 
-2.0
-16.7
 
Gram-positive cocci
   Streptococcus spp.
 
 
 
 
2/2
2/2
100
100
*A patient had more than one isolate. UTI, urinary tract infection; CI, confidence interval; n, number of evaluable patients in each treatment group; n/m, number of pathogens 
with associated favorable assessment/number of patients with an assessment at the early follow-up visit.Park DW, et al.  •  Comparing Ertapenem and Ceftriaxone for Complicated Urinary Tract Infections 
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sponse rates of other complicated UTIs were lower than that of 
APN in both groups.
  In the additional microbiological MITT analyses that included 
202 (74.5%) of the patients randomized, 91 (89.2%) of 102 in the 
ertapenem group and 92 (92.0%) of 100 in the ceftriaxone had a 
favorable microbiological response (95% CI, -11.0 to 5.3), support-
ing the results of the primary analysis. In the combined clinical 
and microbiological efficacy assessment at the DCIV, 61 (92.4%) 
of 66 patients in the ertapenem group and 57 (80.3%) of 71 in 
the ceftriaxone group had the clinical assessment of cure and a 
favorable microbiological response (95% CI, -0.4 to 24.2). At the 
EFU visit, 58 (87.9%) of 66 patients in the ertapenem group and 
62 (87.3%) of 71 in the ceftriaxone group had clinical cure and a 
favorable microbiological response (95% CI, -10.7 to 11.9). 
  Table 4 depicts the microbiological response rates per patho-
gen in the evaluable population at the EFU visit. For all of the 
pathogens listed, the eradication rates were comparable between 
the two treatment groups. A new infection developed in one pa-
tient in the ertapenem group and three patients in the ceftriax-
one group. Six patients in the ertapenem group and four patients 
in the ceftriaxone group had persistence of the original uropatho-
gen. One patient in the ertapenem group and two patients in 
the ceftriaxone group showed persistence with acquisition of 
resistance.
  Among the bacteremic patients, 17 (81.0%) of 21 patients in 
the ertapenem group and 19 (82.6%) of 23 patients in the ceftri-
axone group had a favorable microbiological response. Unfa-
vorable responses in bacteremic patients were due to persistent 
bacteriuria.
Safety and tolerability 
Of all randomized patients who received at least one dose of 
parenteral study drug, 14 (10.6%) of 132 patients in the ertapen-
em group and six (4.4%) of 135 patients in the ceftriaxone group 
had one or more drug-related clinical AEs during parenteral 
therapy. 
  The overall incidence of drug-related clinical AEs was similar 
between the two groups. The most frequent drug-related clini-
cal AEs were diarrhea and nausea; seven (5.3%) and five (3.8%) 
in the ertapenem group and three (2.2%) and one (0.7%) in the 
ceftriaxone group, respectively. No serious drug-related AEs 
were reported in either treatment group.
  The incidence of drug-related laboratory AEs during paren-
teral therapy was not different between the two treatment groups. 
Two (1.6%) patients in the ertapenem group and two (1.5%) pa-
tients in the ceftriaxone group had elevation of alanine amino-
transferase and aspartate aminotransferase levels. 
  Reactions of moderate to severe intensity (pain and swelling) 
at the local infusion sites were reported in two (1.5%) patients in 
the ceftriaxone group, but none in the ertapenem group. Overall, 
the rates of local reactions of any intensity were low, and were 
not different between the two treatment groups.
DISCUSSION
In this multicenter, double-blind, randomized study conducted 
among Korean adults, ertapenem with the option to switch to 
oral therapy was microbiologically and clinically effective and 
tolerated well in patients with APN or other cUTIs. The dosing 
regimen of ertapenem, 1 g once daily, was not therapeutically 
inferior to ceftriaxone, 2 g once daily, followed by an appropri-
ate oral antimicrobial agent. The overall favorable microbiologi-
cal response was 87.9% of the patients receiving ertapenem and 
88.7% of those receiving ceftriaxone. These results are similar to 
those of previous studies with a similar protocol conducted in 
other countries (17, 20, 21). 
  In the additional microbiological MITT assessment, as well 
as in the combined microbiological and clinical response assess-
ment at the DCIV and the EFU visit, the response rate to ertap-
enem therapy was as high as or higher than that to ceftriaxone 
therapy. Enterobacteriaceae accounted for more than 95% of 
the baseline isolates, and E. coli was the most common single 
pathogen. The per-pathogen eradication rates at the EFU visit 
were comparable between the two treatment groups. Most of 
the evaluable patients were switched to oral therapy after clini-
cal improvement with an average 5.7 days of parenteral thera-
py, either with ertapenem or ceftriaxone, which is consistent 
with current medical practice. These findings support the spe-
cific contribution of ertapenem to the total treatment regimen 
as an initial empirical parenteral therapy.
  In this study, overall safety profile and local tolerability of er-
tapenem was similar to those of ceftriaxone. The most common 
ertapenem-related AEs reported were mild gastrointestinal symp-
toms (diarrhea or nausea) and mild to moderate elevation of 
aminotransferase levels. Local reactions at the infusion site were 
infrequent. These findings are consistent with a recent review 
of overall safety and tolerability of ertapenem from 15 clinical 
trials (17, 20-22). 
  The resistance patterns of uropathogens have significantly 
changed over the past few decades worldwide. In the ROK, uro-
pathogenic E. coli are increasingly resistant to trimethoprim-sul-
famethoxazole and ciprofloxacin or levofloxacin (23). Further-
more, the proportion of ESBL-producing E. coli isolates has grad-
ually increased to 8.3%-11.8% (24, 25). In this study, ciprofloxa-
cin resistance and ESBL-producing rates of  E. coli isolates from 
the randomized patients were 22.3% (41/184) and 6.0% (11/182), 
respectively. However, by 2009, the proportion of ESBL-produc-
ing E. coli isolates had increased to 33% overall among the iso-
lates (n = 242) from the Asia-Pacific region (26). Therefore, clini-
cians should choose the right empirical therapy for high-risk 
patients, on the basis of the type of pathogens responsible for 
cUTIs and their resistance patterns. Ertapenem, with rare excep-Park DW, et al.  •  Comparing Ertapenem and Ceftriaxone for Complicated Urinary Tract Infections 
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tions, has a high degree of in vitro activity against antibiotic-re-
sistant urinary isolates of Enterobacteriaceae, including ESBL-
producing K. pneumoniae and E. coli strains (27, 28), and would 
be considered as the first empirical drug of choice for those sit-
uations.
  Our study has a limitation. We did not assess long-term out-
comes of antimicrobial agents such as relapse and recurrence 
rates by late follow-up visit at 4 to 6 weeks. However, relapse or 
recurrence at late follow-up might be mainly due to the under-
lying urinary tract abnormality or inadequate oral therapy rath-
er than failure of the parenteral antimicrobial agent (17).
  In conclusion, our study indicates that ertapenem is not infe-
rior to ceftriaxone in the initial parenteral therapy for cUTIs, in-
cluding APN, on the basis of its clinical and microbiological effi-
cacy as well as safety profiles, and might be used as an alterna-
tive agent.
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